We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+31.05%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.42B
AUM Growth
+$931M
(+37%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
9.36%
Top 10 Holdings %
Top 10 Hldgs %
45.63%
Holding
88
New
10
Increased
35
Reduced
24
Closed
6
Avg Time Held
1.3
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amicus Therapeutics
FOLD
|
+$138M |
| 2 |
Biogen
BIIB
|
+$52.1M |
| 3 |
CELG
Celgene Corp
CELG
|
+$46.9M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$37.1M |
| 5 |
Align Technology
ALGN
|
+$34.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Biopharma Inc
ARRY
|
+$114M |
| 2 |
Cigna
CI
|
+$50M |
| 3 |
Medtronic
MDT
|
+$38.2M |
| 4 |
CVS Health
CVS
|
+$25.1M |
| 5 |
Nightstar Therapeutics plc American Depositary Shares
NITE
|
+$20.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.09% |
| 2 | Financials | 2.23% |
| 3 | Miscellaneous | 1.67% |
| 4 | Energy | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Surgery Partners
SGRY
$1.91B
| $179K | 0.01% |
+15,900
| New | +$200K |
2019 Q1
0 quarters
|
|
77
Viking Therapeutics
VKTX
$3.2B
| $162K | ﹤0.01% |
16,260
| – | – |
2018 Q3
2 quarters
|
|
78
DELISTED
Adverum Biotechnologies
ADVM
| $117K | ﹤0.01% |
2,224
| – | – |
2016 Q2
11 quarters
|
|
79
Aclaris Therapeutics
ACRS
$483M
| $68K | ﹤0.01% |
11,320
| – | – |
2016 Q4
9 quarters
|
|
|
CSLT
80
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $38K | ﹤0.01% |
10,229
| – | – |
2018 Q2
3 quarters
|
|
|
81
CVS Health
CVS
$118B
| – | – |
-382,400
| Closed | -$25.1M | – |
|
82
iRhythm Holdings
IRTC
$3.58B
| – | – |
-3,910
| Closed | -$272K | – |
|
|
83
Medtronic
MDT
$121B
| – | – |
-419,900
| Closed | -$38.2M | – |
|
84
Repligen
RGEN
$11.1B
| – | – |
-6,020
| Closed | -$317K | – |
|
|
SBBP
85
DELISTED
Strongbridge Biopharma plc.
SBBP
| – | – |
-12,500
| Closed | -$56K | – |
|
|
86
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
| – | – |
-1,795,846
| Closed | -$20.7M | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
MFWP
PMG
TIA
Redmile Group's Q1 2019 Portfolio in Review
As of Q1 2019, Redmile Group held 88 positions worth $3.42B, up 37% from $2.49B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Redmile Group deployed $320M of net new capital in Q1 2019, opening 10 new positions and adding to 35 existing holdings. Its largest new stake was Biogen: 165,300 shares worth $39.1M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $114M trimmed.
- Redmile Group's largest Q1 2019 buy was Biogen: 165,300 shares worth $39.1M.
- Redmile Group added most to Amicus Therapeutics in Q1 2019, an estimated $138M increase.
- Redmile Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $114M.
- Redmile Group fully exited Medtronic in Q1 2019, selling an estimated $38.2M.
- Redmile Group's ten largest holdings make up 46% of its $3.42B portfolio in Q1 2019.
- Redmile Group opened 10 new positions and closed 6 in Q1 2019.
- Redmile Group's portfolio value rose 37% quarter-over-quarter to $3.42B.
Based on Redmile Group's 13F filing for Q1 2019, filed 15 May 2019.